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Gene therapyGlanzmann thrombasthenia (GT) is a rare inherited autosomal recessive bleeding disorder of platelet function
caused by a quantitative or qualitative defect of platelet membrane glycoprotein IIb/IIIa (integrin αIIbβ3), a
ﬁbrinogen receptor required for platelet aggregation. Bleeds inGT are variable andmaybe severe andunpredictable.
Bleeding not responsive to local and adjunctive measures, as well as surgical procedures, is treated with platelets,
recombinant activated factor VII (rFVIIa), or antiﬁbrinolytics, alone or in combination. Although platelets are the
standard treatment for GT, their use is associated with the risk of blood-borne infection transmission and may
also cause the development of platelet antibodies (to human leukocyte antigens and/or αIIbβ3), potentially
resulting in platelet refractoriness. Currently, where rFVIIa is approved for use in GT, this is mostly for patients
with platelet antibodies and/or a history of platelet refractoriness. However, data from the prospective Glanzmann’s
Thrombasthenia Registry (829 bleeds and 206 procedures in 218 GT patients) show that rFVIIawas frequently used
in nonsurgical and surgical bleeds, with high efﬁcacy rates, irrespective of platelet antibodies/refractoriness status.
The mechanisms underpinning rFVIIa effectiveness in GT have been studied. At therapeutic concentrations, rFVIIa
binds to activated platelets and directly activates FX to FXa, resulting in a burst of thrombin generation. Thrombin
converts ﬁbrinogen to ﬁbrin and also enhances GT platelet adhesion and aggregation mediated by the newly con-
verted (polymeric) ﬁbrin, leading to primary hemostasis at the wound site. In addition, thrombin improves the
ﬁnal clot structure and activates thrombin-activatable ﬁbrinolysis inhibitor to decrease clot lysis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Figure. Adhesion and aggregation in GT platelets deﬁcient in GPIIb-IIIa (integrin αIIbβ3):
role of factor VIIa. FVIIa-Tissue Factor (TF) complex on TF-bearing cells at the site of vascular
injury activates FX to FXa [25]. FXa-FVa on theTF-bearing cells initiates generation of a small
amountof thrombin (FIIa) that is insufﬁcient to provideﬁbrin formation but sufﬁcient to ac-
tivate GT platelets, causing degranulation and release of FV. FVIIa binds weakly to the neg-
atively charged phospholipid surface [26] of the activated platelets, with the binding
enhanced by the GPIb/IX/V complex [27]. FVIIa at high concentration (attained by high-
dose rFVIIa therapy) can directly activate FX to FXa tomediate generation of a high concen-
tration of thrombin (thrombin burst) [26]. The augmented thrombin generation results in
an increased number of activated platelets deposited (adhesion) to the wound site and
an increased available platelet procoagulant surface to facilitate more thrombin generation
and more platelet activation [28,29]. The augmented thrombin generated also converts
ﬁbrinogen to ﬁbrin. GT platelets lack the ﬁbrinogen receptor (integrin αIIbβ3); therefore,
these platelets cannot use ﬁbrinogen for aggregation. However, binding of ﬁbrin/polymeric
ﬁbrin to an unidentiﬁed platelet surface receptor can mediate aggregation of GT platelets
at the wound site (albeit less potently than ﬁbrinogen-mediated aggregation of normal
platelets) [28,29] following the initial platelet adhesion, resulting in the formation of a
primary hemostatic plug (adopted from Poon [30] with permission from the publisher).
93M.-C. Poon et al. / Transfusion Medicine Reviews 30 (2016) 92–99Glanzmann thrombasthenia (GT) is a rare inherited bleedingdisorder
of platelet function. For bleeding not responsive to local management
and antiﬁbrinolytics, treatment with systemic hemostatic agents is re-
quired. Platelet transfusion is the time-honored standard treatment
for serious bleeding but is not without its shortcomings. Recombinant
activated factor VII (rFVIIa) is emerging as an important therapeutic
agent. This review provides an update on the general understanding
of GT and its management, with emphasis on current thinking on
themechanisms of action of rFVIIa in GT.Wewill brieﬂy touch on hemo-
poietic stem cell transplantation (HSCT) as a curative treatment in care-
fully selected patients with poor quality of life suffering from recurrent
persistent bleeding. Finally, the prospect of gene therapy and the
promising progress made in basic and animal research will be discussed.
GT: General Overview
Eduard Glanzmann, a Swiss pediatrician, ﬁrst described GT in 1918
[1]. GT is characterized by absent or decreased platelet aggregation to
physiologic agonists including adenosine diphosphate (ADP), epineph-
rine, collagen, and thrombin [2–4]; prolonged bleeding time or PFA-100
closure times [5,6]; and abnormal clot retraction [2,7] (Table 1). Platelet
number andmorphology are usually normal [2], as is platelet agglutina-
tion to ristocetin (Table 1) [8], although a few families with
macrothrombocytopenia have been reported [2,9]. These laboratory
ﬁndings are unique toGT. Although platelets in GT patients can undergo
shape change upon stimulation, adhere to exposed subendothelial tis-
sue, and initiate secretion from storage granules [4], they cannot form
platelet aggregates and thrombi at the site of vascular injury [10].
Platelet dysfunction in GT is caused by a quantitative or qualitative
defect of the platelet membrane glycoprotein (GP) IIb/IIIa (integrin
αIIbβ3) complex [3,4,11].αIIbβ3 is a heterodimeric molecular complex
acting as a ﬁbrinogen receptor [12,13], which is important formediating
platelet aggregation induced by physiologic agonists and for ﬁbrin clot
retraction. When platelets are activated, αIIbβ3 responds to inside-out
signaling and transforms from its bent resting state to a straight active
conﬁguration required for ﬁbrinogen binding [14–16]. Other αIIbβ3
ligands include the adhesive proteins vonWillebrand factor,ﬁbronectin,
vitronectin, and CD40L [17–19]. Platelets with deﬁcient or defective
αIIbβ3 cannot bind to these adhesive proteins when stimulated
(Figure), which accounts for the characteristic GT laboratory ﬁndings.
GT is a rare autosomal recessive disorder with an incidence of approxi-
mately 1 per million. However, in areas where marriage between close
family relatives is common, the incidence can be as high as 1:200000
[20]. The genetic defect resides on the ITGA2B or ITGB3 gene encoding
αIIb and β3, both located on chromosome 17 (12q21) [3,4,9,21,22].
Mutations affecting either gene can result in GT. The multitude of
mutations reported and how they result in quantitative or qualita-
tive αIIbβ3 defects in GT have recently been extensively reviewed
by Nurden and colleagues [4,9]. Details are also available at
http://sinaicentral.mssm.edu/intranet/research/glanzmann/menu.
Currently (as of October 25, 2015), there are 255 mutation records on
the ITGA2B gene and 164mutation records on the ITGB3 gene. Although
themajority aremissensemutations, nonsensemutations (causing pre-
mature termination), small deletions and insertions (with in- or out-of-
frame shifts, some causing altered splicing or premature terminationTable 1
Diagnosis and classiﬁcation of GT
Type Proportion of
GT patients
αIIbβ3 expression
(platelet membrane)
αIIbβ3 (%) (ﬂow
cytometry: CD41:
αIIb CD61: β3)
Platelet ag
(ADP, EP,
thrombin)
Type I ~75% Absent or trace expression 0-5 Nil
Type II ~15% Substantially reduced 5-20 Nil
Variant ~10% Abnormal αIIbβ3 which
cannot bind ﬁbrinogen
N20 Nil/abnorm
Platelet countandmorphologyareusuallynormal, althougha fewfamilieshavebeenreported tohavemand loss of transcript), as well as intronic splice site alterations are
also reported. Integrin synthesis occurs in the megakaryocytes with
αIIbβ3 complex formation in the endoplasmic reticulum. Any
noncomplexed or incorrectly folded gene products will fail to undergo
processing in the Golgi apparatus and are rapidly degraded intracellularly
[4,9,23,24]. In GT, homozygosity of the same mutation is often a result
of consanguineous marriage, although many other patients may be
compound heterozygous for different mutations from each parent.
Bleeding symptoms are conﬁned to GT patients who are homozygous
or compound heterozygous for αIIbβ3 mutations, whereas simple
heterozygotes are asymptomatic [11], so family bleeding history may be
absent. Integrin subunit αIIb expression is exclusively for αIIbβ3 in
platelets. However, subunit β3 is involved in other integrins outside
platelets. The impact of β3 loss (that results in GT) on other tissues is
currently unknown.
GT can be classiﬁed according to platelet membrane αIIbβ3 protein
levels measured using ﬂow cytometry using monoclonal antibodies
CD41 (for αIIb) and CD61 (for β3) [31,32]. As shown in Table 1,gregation
collagen,
Platelet agglutination
(ristocetin)
Bleeding time/
closure times
(PFA-100)
Clot
retraction
α-Granule
pool ﬁbrinogen
Normal Prolonged Nil Nil
Normal Prolonged Residual Subnormal
al Normal Prolonged Variable Variable
acrothrombocytopenia (see text).Abbreviations:ADP,adenosine5'-diphosphate;EP, epinephrine.
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α-granule pool ﬁbrinogen, and absent clot retraction), 15% are type II
(5%-20% αIIbβ3 with diminished platelet ﬁbrinogen and normal or di-
minished clot retraction), whereas 10% are variant GT (N20%αIIbβ3, de-
fective receptor function with variable platelet ﬁbrinogen content and
clot retraction) [11,33,34].
Bleeding phenotype in GT is heterogeneous (from mild to severe),
and the relationship to GT genetic mutations and GT type has not
been elucidated. Linkage between the bleeding phenotype and the
platelet α2 C807T polymorphism [35] has been reported in a small
group of GT patients, suggesting that a milder bleeding phenotype
occurs in patients with α2 807-T/T (compared with T/C or C/C) [35].
Typically, patients with GT develop bleeding symptoms early in
childhood, although some symptomatic children may improve when
they reach adulthood. Of the patients enrolled in the Glanzmann’s
Thrombasthenia Registry (GTR) [36,37], age of ﬁrst bleeding symptom
was available in 187 (enrolled at age 0.05-50 years). First bleed
symptoms occurred at a median age of 1 year (mean, 5.6 years), with
53% by the age of 1 year and 85% by the age of 14 years (unpublished
data). GTR is a prospective observational, international registry that
enrolled 218 patients with GT from 45 sites in 15 countries worldwide
and collected data on effectiveness and safety of rFVIIa and other treat-
ment modalities on 829 bleeding (184 patients) and 204 surgical
episodes (97 patients) [36,37]. The bleeding manifestations of 216 of
these GT patients are listed in Table 2, which also provides comparative
data reported from previous GT patient series [11,20,38]. Bleeding
episodes are typically mucocutaneous and include easy bruising,Table 2
Number and percentage of GT patients who have had at least 1 clinical manifestation⁎
GTR⁎
Total N = 216
(M/F = 92/124)
n (%)
George et al, 1
Total N = 177
(M/F = 75/10
n (%)
Epistaxis 159 (79.2) 129 (72.9)
Gingival bleeding 135 (61.9) 97 (54.6)
Dental bleeding§ 82 (37.6) –
Menorrhagia (female) 67/91⁎⁎ (73.6) 54/55 (98.2)
Bleeding at childbirth 7/91 (7.7) –
Ruptured ovarian follicle/cyst 2/91 (2.2) –
Easy bruising/purpura/petechiae 94 (43.1) 152 (85.9)
Subcutaneous hematoma 82 (37.6) –
Muscle hematoma 28 (12.8) –
Hematoma; unspeciﬁc – –
Gastrointestinal bleeding 50 (22.9) 22 (12.4)
Hemorrhoidal bleeding 12 (5.5) –
Hemarthrosis 14 (6.4) 5 (2.8)
Hematuria 15 (6.9) 10 (5.6)
Circumcision bleeding 11 (5.0) –
Cephalohematoma 1 (0.5) –
Bleeding after minor trauma 10 (4.6) –
Bleeding from vaccination 3 (1.4) –
Umbilical cord bleeding – –
Hemoperitoneum 6 (2.8) –
Hemopericardium 1 (0.5) –
Intrahepatic hematoma – 1 (0.6)
Central nervous system bleeding 4 (1.8) 3 (1.7)
Ear bleeding – –
Subconjunctival bleeding 2 (0.9) –
Abbreviations: M/F = male/female.
⁎Data are available on 216 of 218 GT patients enrolled in GTR; bleeding manifestations include
admissions (whether treated or not), and those recordedwith a history ofmanifestations before
tively and recorded in GTR, 199 (24%) were posttraumatic bleeds [36]. Whether some of the ble
to those reported as bleeding fromminor trauma) were not clearly reported. The GTR recorded
cedures before GTR registration/admission (apart from dental bleeding, which includes decidu
The ﬁnal number is higher than the total number of patients because many patients have mor
§Dental bleeding also includes deciduous teeth eruption and removal, and dental extractions.
⁎⁎Menorrhagia: calculation based on number of women aged 12 years or older; not included in
¶¶Calculation based on women of reproductive age.
Patient population: *various ethnic groups from 15 countries; ¶various ethnic groups: 64 French
cumulative databases, it could not be ascertained whether patients from one database were rep
overlapping less likely to occur.purpura, epistaxis, gingival and other mouth bleeding, menorrhagia,
and gastrointestinal bleeding [11,20]. Less frequent bleeding episodes
include hemarthrosis and central nervous system bleeding. Bleeding
complications are frequent after trauma and surgical procedures
including dental extraction, as well as during/after child birth. Sociocul-
tural factors and prevailing moral values may prevent some women
from discussing menorrhagia even in clinical settings [39], which may
account for the discrepancy in menorrhagia rates in different series.
Bleeding severity in GT is variable and unpredictable and appears to
bear little relationship to GT classiﬁed according to platelet membrane
αIIbβ3 protein levels (ie, types I, II, and variant) [11] or to genetic mu-
tation, as the severity of bleeding may differ even among patients
with the same genetic mutation [35], suggesting involvement of other
genetic/nongenetic factors in determining the bleeding phenotype in
these patients. Overall, GT is considered a severe bleeding disorder,
and serious bleeding may be fatal, although overall the mortality rate
in GT is relatively low. In a series of 64 French GT patients reported by
George et al [11], 54 (84%) had a history of red cell transfusion. Epistaxis
is common, particularly in children, and can be so severe as to require
transfusion [11,40]. Menorrhagia can be a critical bleeding problem,
with a particularly high risk of severe and prolonged bleeding requiring
transfusion at menarche.
Hemostatic Management
Management options for the treatment of GT bleeding include local
and adjunctive measures for mild bleeding. However, when local990 [11]¶
2)
Toogeh et al, 2004 [20]†
Total N = 382
(M/F = 204/178)
n (%)
Borhany et al, 2012 [38]ǂ
Total N = 43
(M/F = 20/23)
n (%)
190 (49.7) 29 (67.4)
87 (22.8) 19 (44.1)
– –
17/132¶¶ (12.9) 5/5¶¶ (100)
– –
– –
58 (15.1) 25 (58.1)
– 5 (11.6)
– –
18 (4.7) 4 (9.3)
18 (4.7) 9 (21.0)
– –
1 (0.3) –
– 6 (14.0)
14/204 (6.8) 12/20 (60)
– –
– –
– –
1 (0.3) –
– –
– –
– –
1 (0.3) –
– 4 (9.3)
– –
those recorded at GTR registration (whether bleeding symptoms were reported or not),
GTR registration/admissions. Of the 829 bleeding episodes (184patients) treated prospec-
edingmanifestations before GTR registration/admissionwere trauma induced (in addition
treatments to prevent surgical bleeding [37]. However, history of bleeding following pro-
ous tooth removal and dental extraction§) and following circumcision were not reported.
e than 1 clinical manifestation (median 4, mean 3.69, range 0-10).
calculation: “vaginal bleeding” occurring in one 11-year-old girl.
plus 113 from the literature; †Iranians; ǂPakistani. Although these are distinct rather than
orted in another. However, the timing of the different databases wouldmake instances of
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the use of systemic hemostatic agents such as platelets and rFVIIa is
required. Currently, rFVIIa is approved in the European Union for GT
patients with platelet antibodies (to human leukocyte antigen [HLA]
and/or αIIbβ3) with past or present platelet refractoriness, whereas in
the United States, it is approved for GT patients with refractoriness to
platelet transfusions (with or without antibodies to platelets), and in
Canada, it is approved for patients with clinical refractoriness and/or
platelet antibodies or when platelets are not immediately available
[41–43]. However, data from the international, observational GTR,
established in 2004 [36,37], suggest that rFVIIa is frequently used off-
label for bleeding and surgical procedures, irrespective of platelet anti-
bodies and/or platelet refractoriness, and the proportion of treatments
rated “effective” was similar to those treated with other modalities.
Nonsurgical bleeds were resolved in 91% (111/122) episodes treated
with rFVIIa alone, 82.7% (86/104) treatedwith rFVIIa+antiﬁbrinolytics,
72.7% (48/66) treated with rFVIIa + platelets ± antiﬁbrinolytics, 78.8%
(245/311) treated with platelets ± antiﬁbrinolytics, and 84.7%
(183/216) treated with antiﬁbrinolytics [36]. For surgical bleeds in pa-
tients without platelet antibodies or refractoriness, the efﬁcacy rate was
100% for both minor and major procedures using rFVIIa alone (minor
24/24; major 4/4), rFVIIa + antiﬁbrinolytics (minor 17/17; major 3/3),
and platelets ± antiﬁbrinolytics (minor 11/11; major 5/5) [37]. In pa-
tients with antibodies and refractoriness undergoing minor procedures,
efﬁcacy rates were 88.9% (16/18) for rFVIIa alone, 100% (19/19) for
rFVIIa + antiﬁbrinolytics, 66.7% (2/3) for platelets ± antiﬁbrinolytics,
and 100% (3/3) for rFVIIa + platelets ± antiﬁbrinolytics [37]. Eleven
major procedures were performed in patients with platelet antibodies
and/or refractoriness. Of these, effectiveness was 100% (2/2) for
rFVIIa alone, 50% (2/4) for rFVIIa + antiﬁbrinolytics, 100% (2/2) for
platelets ± antiﬁbrinolytics, and 66.7% (2/3) for rFVIIa + platelets ±
antiﬁbrinolytics. Dosage schedules of rFVIIa for both nonsurgical and
surgical bleeds were in line with those previously reported or recom-
mended for GT patients (≥80 μg/kg every ≤2.5 hours for nonsurgical
bleeds; 90-140 μg/kg every ≤2.5 hours for ≥2 doses for minor surgery,
and more doses for major surgery until hemostasis is secured) [36,37].
The GTR data also reveal a low frequency of adverse events (AEs)
associated with rFVIIa use for both nonsurgical and surgical bleeds.
Thirty-ﬁve AEs were associated with nonsurgical bleeds, 11 of which
occurred in patients receiving treatments that included rFVIIa; 3 AEs
in 1 patient were possibly or probably related to rFVIIa (nausea,
dyspnea, and headache) [36]. There were no thromboembolic events
among patients treated with rFVIIa for nonsurgical bleeds. Among pa-
tients undergoing surgery, 1 of 4 reported AEs was judged to be related
to rFVIIa (nonfatal thromboembolic event in an adult woman treated
with rFVIIa + platelets + antiﬁbrinolytics) [37].
These results from the GTR, with the largest data collection thus far,
suggest that rFVIIa may be effective with no safety concerns in patients
with GT both with and without platelet antibodies and/or platelet
refractoriness. However, generalization of these results cannot be
made without caution, as data from registries are inherently limited
by voluntary participation of enrollment centers from different coun-
tries with no guarantee of exhaustiveness in reporting all treatment
cases. In this respect, although rFVIIa has recently gained approval in
Canada for use in GT patients with refractoriness and/or platelet-
speciﬁc antibodies, it is of note that rFVIIa is also approved where
platelets are not immediately available [41].
Platelet Transfusion as Current Standard Treatment of GT
To date, the standard treatment for serious bleeding and coverage of
surgical procedures has been platelet transfusion. Platelets are naturally
effective in nonimmune quantitative and qualitative platelet disorders.
However, in addition to allergic and immune reactions (anaphylaxis
and transfusion-related acute lung injury being the most serious),
other potential risks associated with platelet transfusion includeblood-borne pathogen transmission and immunization. Furthermore,
platelet concentrates, particularly HLA-matched single-donor and
leukocyte-reduced apheresed platelets, may not be readily available in
some areas or for emergency use.
Blood-Borne Pathogen Transmission
The residual risk of blood-borne virus infection is now very low.
Canadian data suggest that the risk per donor exposure was 1:7.8 million
for HIV, 1:2.3 million for hepatitis C virus, 1:153 000 for hepatitis B virus,
1:4.3 million for human T-cell lymphotropic virus, and b1:1 million for
West Nile virus [44,45]. In contrast, bacterial contamination of platelet
concentrate remains the most prevalent risk for transfusion-associated
infection because of the storage of platelets at 20°C-24°C, a condition
that facilitates bacterial proliferation [46]. Process improvements and
monitoring using bacterial culture systems reduced the risk (as of 2009)
of transfusion-associated sepsis at around 1:12000 for pooled whole-
blood–derived platelets and 1:60000 for single-donor (apheresis)
platelets; these risks were much higher when improvements were not
implemented, being 1:3000 for pooled whole-blood–derived platelets
and 1:15000 for single-donor platelets [47]. A recent review by Katus
et al (2014) [48] estimated the residual risk of the transfusion of bacte-
rially contaminated platelets to be 127 to 1885 permillion units. Impor-
tantly, transfusion-associated sepsis is frequently not recognized by
physicians, such that the actual prevalence may be higher, and the cor-
relation between bacterial load and clinical outcome remains ill deﬁned
[49,50]. The 2011 report reviewingdata from12 Canadian BloodAgency
production sites [51] suggested that although bacterial testing of plate-
let components and implementation of improved protocols were incre-
mentally effective in reducing the risk of transfusion of bacterially
contaminated platelet concentrates, false-negative bacterial culture
screening results, implicated in adverse transfusion reaction, continued
to occur [51]. Nonetheless, continuous efforts by the transfusion medi-
cine community to reduce bacterial contamination have been effective.
The last documented conﬁrmed transfusion-transmitted bacterial
infection in the United Kingdom was in 2009, predating universal
bacterial culture of platelets. However, there were 2 “near misses” in
2014, where 2 separate units of apheresis platelets were observed by
hospital blood banks to have clumps and were not transfused; culture
of both units later identiﬁed growth of Staphylococcus aureus [52]. In
the United States, there were only 2 Food and Drug Administration re-
ports of transfusion-related fatalities due to bacterial contamination of
apheresis platelets in 2012. There have been only 5 probable or likely
septic transfusion reactions between 2007 and 2014 (out of
approximately 646000 platelet doses transfused) reported by the
Canadian Blood Services (personal communication, DrMindy Goldman,
Canadian Blood Services, Canada). In addition to the risk of known
blood-borne pathogens, emerging agents, potential or actual, and
their potential for severe clinical outcomes (most signiﬁcantly variant
Creutzfeldt-Jakob disease or variant Creutzfeldt-Jakob disease prions,
dengue fever virus, Babesia sp, xenotropic murine leukemia-related
virus, and protozoa) were recently reviewed by the blood banking/
transfusion and bleeding disorders community [53–55].
Platelet Immunization
About 50% of nonimmune thrombocytopenic patients receiving
platelet transfusion will develop antibodies against the HLAs [56–58],
although the incidence is lower (15%-17%) if leukoreduction of the
platelet component is practiced [56–58]. GT patients may also develop
antibodies to the plateletmembrane surfaceαIIbβ3 antigens. Such anti-
bodies could conceivably result in inhibition ofαIIbβ3 function or in the
accelerated clearance of the αIIbβ3-bearing platelets. In our previous
survey of 59 GT patients treated with rFVIIa, 29 patients (49%) had
platelet antibodies (21 against αIIbβ3 and 13 against HLA, with 5
patients having antibodies against both) [59]. In the GTR, of 218 GT
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antibodies (47 against αIIbβ3 and 21 to HLA; unpublished data). In
1 study, 4 of 16 (25%) GT patients followed over a 30-year period
developed antiplatelet antibodies: 2 against HLA, 1 against αIIbβ3, and
1 against both [60]. Recent studies suggest that anti-αIIbβ3 antibodies
are more likely to develop in patients with homozygous or compound
heterozygous mutations that result in premature protein termination
[61]. Thus, anti-αIIbβ3 antibodies developed in as many as 13 of
16 (81%) patients with the French Manouche Gypsy mutation (with
absence of the αIIbβ3 complex) but only in 2 of 8 (25%) patients with
less drastic mutations [61]. Although these ﬁndings await conﬁrmation
in a larger study, which should take into account both the GT genotype
and immune-response–modifying gene changes, thiswas theﬁrst study
to suggest a possible relationship between αIIbβ3 gene mutation and
the propensity to develop anti-αIIbβ3. Hence, the genetic analysis of
GT patients appears to be important; for patientswith knownmutations
that result in truncated or absentαIIbβ3 complex, it may be prudent to
suggest that platelet transfusion should be avoided to prevent αIIbβ3
immunization [61]. In the absence of molecular data, some clinicians
were concerned by the risk of immunization with platelet transfusion
and preferred the use of rFVIIa [59].
The development of platelet antibodies may be associated with
refractoriness to future platelet transfusion. This occurs in approximately
50% of patients with anti-HLA antibodies [58,62,63] and is frequent in
patients with anti-αIIbβ3 antibodies [59]. Transfused platelets in GT
patients with anti-αIIbβ3 may not always be removed immediately
[61,64], postulated to be dependent on antibody isotype. Flow cytometry
is required to assess the presence of surviving donor platelets after trans-
fusion [64], but this is not always available in every center at all times.
Without readily available methods to predict which patients with a
history of anti-HLA or anti-αIIbβ3 will be refractory to platelets, the
avoidance of platelet transfusion is preferred in these immunized GT
patients. However, for severely bleeding GT patients, when alternative
therapies fail to secure hemostasis, transfusion with large doses of
platelets, with or without antibody removal by plasmapheresis [65] or
immunoabsorption [66], should still be attempted.
In contrast, for some patients with a history of platelet refractoriness,
antibodies are not always detectable, possibly because the refractoriness
is due to the presence of other clinical factors (eg, sepsis, splenomegaly),
presumably because the antibodies have disappeared in the absence of
new transfusions, or because the antibody titers may be below that able
to be detected by the antibody assay used. In an earlier survey of 59 GT
patients treated with rFVIIa, platelet antibodies were detected in 17 of
23 patients with a history of platelet refractoriness [59], whereas in the
GTR, a history of platelet antibodieswas reported in only 24 of 34 patients
with a history of refractoriness (unpublished data). Anti-αIIbβ3may also
transfer across the placenta during pregnancy, potentially causing throm-
bocytopenia and bleeding in the fetus and/or the newborn infant
[60,61,67–70]. Thus, it is prudent to avoid platelet transfusion in girls
and women of reproductive age to prevent anti-αIIbβ3 immunization.
Recombinant Activated Human Factor VII
Pharmacokinetics and Clearance of High-Dose rFVIIa
The pharmacokinetics of rFVIIa have been studied in hemophilia and
FVII deﬁciency. In severe hemophilia patients in the nonbleeding state
who were given a single dose of rFVIIa at 90 μg/kg, the estimated
mean initial and terminal half-life was 0.6 and ~2.6 hours, respectively
[71]. A similarmean terminal half-lifewas also reported in children (2.6
vs 3.1 hours in adults; rFVIIa dose: 90-180 μg/kg) [72] and in patients
with FVII deﬁciency (~3 hours, nonbleeding state) [73]. The plasma
level of FVII increased proportionally with increasing dose when multi-
ple doseswere tested. Of note is the ﬁnding of Villar and colleagues [72]
that the total body clearance normalized for body weight was signiﬁ-
cantly faster in children than in adults (FVII:C, 58 vs 39 mL kg−1 h−1
and FVIIa, 78 vs 53 mL kg−1 h−1). A trend toward a larger volume ofdistribution at steady state in children than in adults was also observed
[72]. These ﬁndings suggest that higher doses of rFVIIa may be needed
in children to achieve the same plasma levels as adults; results from
the GTR demonstrate that children required more rFVIIa (expressed in
μg/kg) to stop bleeding than that reported for adults [74].
In the circulation, infused rFVIIa is principally cleared by its complex
formation with antithrombin, accounting for 65% of an intravenous
90-μg/kg dose of rFVIIa in a hemophilia patient [71]. Inmice, hepatocytes
and Kupffer cells were also involved in the hepatic clearance and
metabolism of both full-length rFVIIa and rFVIIa complexed with anti-
thrombin and α2-macroglobulin [75,76].
How Does High-Dose rFVIIa Work in GT?
Physiologically, FVIIa exerts its hemostatic effect after being com-
plexed with tissue factor (TF). In normal individuals, FVIIa-TF complex
formation on TF-bearing cells at the site of vascular injury activates FX
and FIX to result in an initial thrombin generation that activates a number
of clotting factors (eg, FV, FVIII, FXI) aswell as platelets. Activated platelets
are recruited to thewound sitewhere they aggregate,mediated in part by
the binding of soluble ﬁbrinogen to platelet surfaceαIIbβ3 [12,14–16], to
form the primary hemostatic plug. Activated platelets at the wound site
support further coagulation activation to result in thrombin generation
sufﬁcient forﬁbrin formation andhemostasis (the “thrombin burst”) [25].
In GT, although this TF mechanism is important in generating the
initial thrombin on TF-bearing cells required to initiate platelet activa-
tion at the site of tissue injury, the initial thrombin generated is not
sufﬁcient to result in platelet aggregate formation required to support
thrombin burst at the vascular injury site (because of the lack of
αIIbβ3 receptors for ﬁbrinogen binding). GT platelets therefore have
impaired thrombin generation capacity [77,78]. Experimental evidence
suggests that high-dose rFVIIa supports hemostasis in GT via a TF-
independent mechanism (Figure). High-dose rFVIIa can bind with a
low afﬁnity (Kd ~100 nmol/L) to the negatively charged phospholipid
surface exposed on activated platelets [26], enhanced by the GPIb/IX/
V complex on the platelet membrane surface [27]. At high concentra-
tions, bound rFVIIa was able to activate FX to FXa directly, resulting in
a burst of thrombin generation and enhancing hemostasis in GT by im-
proving GT platelet adhesion and aggregation [28,29].
Enhanced thrombin generation from rFVIIa bound to activated plate-
lets at high concentrations also improves ﬁbrin clot structure not only in
hemophilia plasma [79] but also in plasma from a patient with GT,
improving hemostasis by decreasing clot permeability and tightening
the ﬁbrin network [80]. Similar improvement in ﬁbrin structure was ob-
served using confocal 3-dimensional microscopy of clots formed during
thrombin generation after the use of GT platelet-rich plasma obtained
after in vivo administration of therapeutic rFVIIa [78]. Two other recent
observations of rFVIIa action in hemophilia and other bleeding disorders
may also be pertinent in GT: (1) rFVIIa added to normal, FVII-deﬁcient,
and Bernard-Soulier syndrome platelet-rich plasma was shown to inter-
nalize to the platelet cytoplasm and redistribute to the open canalicular
system and α-granules [81], thereby improving platelet aggregation and
ﬁbrin generation in perfusion studies. Whether this rFVIIa action occurs
in GT has not yet been studied. (2) Infusion of rFVIIa in hemophilia pa-
tients with inhibitors also results in a transient increase in procoagulant
platelet microparticles that promotes hemostasis [82]. Whether rFVIIa
also releases platelet microparticles in GT remains to be explored.
Curative Management
HSCT as Current Curative Treatment
Although currently available treatment strategies for GT are very
effective with a good safety proﬁle, a small number of GT patients may
continue to have persistent and recurrent life-threatening bleeding
refractory to current hemostatic treatments, particularly patients with
platelet antibodies and refractoriness. Management with HSCT is a
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resulting in the correction of the bleeding disorder and improved
quality of life. Between 1981 and 2015, 43 GT patients who underwent
an allogeneic HSCT (age: median 9 years, range 1-53) have been regis-
tered with the Center for International Blood and Marrow Transplanta-
tion Research (CIBMTR) with various donor and graft sources and
conditioning regimens. As ofOctober 16, 2015, 35 (81%) transplantedpa-
tients remained alive, 3 (7%) were dead, and 5 (12%) were missing at a
median 47months (range, 3-120) of follow-up of survivors (preliminary
data obtained from the Statistical Center of the CIBMTR; the analysis has
not been reviewed or approved by the Advisory or Scientiﬁc Committees
of theCIBMTR). A reviewof the literature found reports of at least 16 chil-
dren (7 boys, 9 girls; age 13months to 16 years, median 4.22 years) who
had undergone 17 HSCTs, primarily for type I GT with a serious bleeding
phenotype [83–91]. Of the 16 transplants that were successful, HLA-
matched stem cell transplantation (SCT) sources included bone marrow
from siblings (n = 10, 5 with heterozygous GT [84,85,88,90,91], 5 pre-
sumed normal [83,86,87]) and unrelated normal donors (n =
2) [83,86], peripheral blood from matched family members (n =
2) and unrelated cord bloods (n= 2) [89]. Successful conditioning regi-
mens included full-intensity (myeloablative) conditioning in 13 [83–91]
and reduced-intensity conditioning in 3 [86]. All but 1 of the
successful transplantations resulted in complete engraftment. One
child receiving peripheral blood stem cells from a matched family
donor following reduced-intensity conditioning resulted in mixed
chimerism with 30% of the donor cells, which was sufﬁcient to correct
the bleeding disorder [86]. The only HSCT failure was the ﬁrst patient
reported by Bellucci and colleagues [84]; the boy rejected the initially
transplanted graft following reduced-intensity conditioning but was
successfully retransplanted from the same sibling donor using a full-
intensity conditioning regimen. It is uncertain whether reporting bias
exists such that cases of unsuccessful transplantation have not
been reported.
In addition to the 16 children transplanted primarily for GT, a
52-year-old man with acute myelogenous leukemia (FAB-M2) and
type I GT as a comorbid conditionwas also reported to have successfully
undergone transplantation of marrow stem cell from an unrelated
donor following a full-intensity conditioning regimen [92].
Although HSCT merits careful consideration for the treatment of
selected GT patients with persistent and life-threatening hemorrhage,
the decision to transplant must be weighed against the signiﬁcant
risks associated with HSCT. Paradoxically, serious hemorrhage may be
caused during the peritransplant period, especially when anti-αIIbβ3
development coincides with routine procedures including central
venous catheter placement or conditioning-associated mucosal disrup-
tion [89], and during the thrombocytopenic phase [91]. For example,
tunneled central venous catheter placement almost resulted in a fatal
hemorrhage in 1 patient [89]. Graft-vs-host disease (acute and/or
chronic) may also develop and require immunosuppressive treatment.
Full-intensity conditioning may also carry considerable adverse effects
such as infertility, growth retardation, and the risk of secondary malig-
nancy [86]. Although reduced-intensity conditioning may reduce
morbidity and mortality, the risk of graft rejection is higher than with
full-intensity conditioning and HSCT [84,86,89].
Gene Therapy as Potential Future Curative Treatment
Although gene therapy remains experimental, the prospect that this
technology may become a viable treatment option for patients has im-
proved with the signiﬁcant progress made in in vitro culture and in an-
imal studies. Wilcox and colleagues [93] demonstrated that
transduction of granulocyte-colony stimulating factor–mobilized pe-
ripheral blood stem cells with an oncoretrovirus vector encoding
integrin β3 generated de novo synthesis of viable integrin αIIbβ3 com-
plex on megakaryocytes from human GT patients with ITGB3mutation.
Furthermore, in a murine GT model (ITGB3mutation), transplantationof bonemarrow transducedwith a lentivirus vector encodingβ3 resulted
in the correction of platelet function [94]. It was therefore hypothesized
that transplanting autologous hematopoietic stem cells transduced with
genes encoding normal integrin αIIb or β3 could result in de novo syn-
thesis of a biologically normal integrin αIIbβ3 within megakaryocytes
and allow trafﬁcking of the entire receptor to the cell surface of the plate-
lets produced [95]. A GT dog gene-therapy model (Great Pyrenees with
ITGA2Bmutation) was established by transplanting granulocyte-colony
stimulating factor–mobilized autologous peripheral blood stem cells
transduced with lentivirus vector encoding human αIIb [95]. For each
of the 3 dogs, followed for 2, 4, and 5 years, the percentage of platelets
that expressed αIIbβ3 stabilized to approximately 10% of the total plate-
let population [95]. Although this level ofαIIbβ3 is considered pathologic
in humans (in keeping with that observed in type II GT), it was sufﬁcient
to result in signiﬁcantly decreased cutaneous bruising and shortening of
the mucosal bleeding time [95]. Blood loss was reduced 20- to 135-fold
as comparedwith the control dogs. Laboratory studies also demonstrated
partial correction of aggregation of washed platelets to a mixture of
activation agonists (ADP, epinephrine, and canine thrombin receptor–
activating peptides: TRAP-1, -3, and -4), improved platelet adhesion on
immobilized ﬁbrinogen, and improved clot retraction [95].
Recently, Sullivan and colleagues [96] reprogrammed monocytes of
2 type I GT patients with ITGA2Bmutations to induce pluripotent stem
cells (iPSC). Insertion of GP1ba promoter-driven human αIIb cDNA
into the AAS1 locus of the iPSCs resulted in high expression of αIIb
mRNA and protein in the iPSC-derived megakaryocytes that responded
to agonist stimulation, suggesting recovery of cell surface integrin
αIIbβ3 expression and activation.
Although these studies represent a milestone toward gene therapy in
human GT, further improvements are required for its clinical develop-
ment. Efﬁcient and safe vectors designed to enable transgene delivery
and stable, high expression in humans are required. Furthermore, strate-
gies need to be developed to overcome elimination of the vector or gene
products by host immune response and also to prevent insertional muta-
genesis of the transgene.
Conclusions
Since the time of its ﬁrst description in 1918 [1], GT has become a
well-understood congenital bleeding disorder of platelet membrane
surface integrin αIIbβ3 with salient clinical, laboratory, biochemical,
and genetic features. Because of the rarity of this disorder, understanding
of itsmanagement has been hindered because few clinicians have exten-
sive experience with GT, and randomized clinical trials are difﬁcult to
perform. Currently available hemostatic agents for GT patients with
bleeding unresponsive to conservative treatment or undergoing surgical
procedures include platelet transfusion and rFVIIa. Although platelet
transfusion is a time-honored and effective treatment for GT patients,
one of its disadvantages is that a proportion of patients who develop
antibodies to HLA and/orαIIbβ3 are refractory to this treatment. In addi-
tion, as with other blood products, blood-borne pathogen transmission,
in particular bacterial infections, is a concern, and much research is in
progress to improve processes and to develop bacterial culture systems
to lessen this risk. Recombinant FVIIa, as an alternative hemostatic
agent, has been reported to be effective with a good safety proﬁle.
Much progress has been made over the past 10 years in understanding
themechanisms of action of rFVIIa in effecting hemostasis in GT. Curative
treatment with HSCT is possible but only with considerable risk of
HSCT-related adverse effects and should be considered exclusively
for patients with persistent severe bleeding refractory to hemostatic
treatment modalities following careful risk/beneﬁt assessment. Gene
therapy is a curative therapy for the future, and its progress is impres-
sive and promising.
The GTR has prospectively collected data from 45 clinics from 15
countries on the treatment of 829 bleeding episodes in 184 GT patients,
and 206 surgical procedures in 96 GT patients, with rFVIIa and/or
98 M.-C. Poon et al. / Transfusion Medicine Reviews 30 (2016) 92–99platelets and/or antiﬁbrinolytics [36,37]. To date, theGTR represents the
largest collection of data available on the treatment of bleeds in GT. It is
hoped that these data will contribute toward the development of
clinical “recommendations” for the management of GT patients using
platelets or rFVIIa until a higher level of evidencemay become available
from randomized clinical trials (which are difﬁcult to achieve because of
the rarity of the disorder) or until a safe curative treatment is available.
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